Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Study to Evaluate Safety and Efficacy of Allogeneic Bone-Marrow Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease

NCT02594839 is registered in ClinicalTrials.gov with Federal Research Clinical Center of Federal Medical & Biological Agency, Russia as lead sponsor.

NCT NCT02594839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02594839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Study to Evaluate Safety and Efficacy of Allogeneic Bone-Marrow Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease
Lead sponsor
Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2013
Completion date
January 31, 2018
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic interstitial pneumonia, idiopathic pulmonary fibrosis, interstitial lung disease